Friday, August 21, 2015

Former President Carter Receiving Merck's Keytruda® -- Investigational/Experimental Use; Off Label -- For Brain Tumors

I half-wondered if Mr. Carter would receive the BMS (Opdivo®) or Merck (Keytruda®) breakthrough therapy, when I read of his interview, last evening, in the Gray Lady. Now we know -- he will. And we may well see outstanding results, even for a patient in his 90s. It is indeed a heady time for science.

I'll have more later -- on a train, at the moment. . . This could be a nice institutional marketing coup -- for Kenilworth, if he sees any progression free survival, of statistical significance.

Okay -- do go read it:

. . . [The former President] immediately began treatment with a drug that’s new to the market. Carter is receiving pembrolizumab, better known by its brand name, Keytruda, according to the Washington Post. . . .

Of course, since the use is experimental -- and prescribed directly by his oncologists -- presumably without any input from Merck, proper, there is no off-label regulatory concern, for Merck. More soon... Onward -- and we wish Mr. Carter the very best here.

No comments: